Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...
In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.
4don MSN
Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell ...
CORONADO, Calif. — Despite recent advances in the treatment of cutaneous squamous cell carcinoma (SCC), a lack of consensus ...
Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) ...
Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) ...
Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful anti-cancer immune ...
A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal ...
Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback